Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ONC-392 |
Synonyms | |
Therapy Description |
ONC-392 is a pH-sensitive monoclonal antibody that targets CTLA4 (CD152), potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ONC-392 | ONC392|ONC 392 | CTLA4 Antibody 24 Immune Checkpoint Inhibitor 151 | ONC-392 is a pH-sensitive monoclonal antibody that targets CTLA4 (CD152), potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | 1 |
NCT05671510 | Phase III | ONC-392 Docetaxel | Study of ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer (PRESERVE-003) | Not yet recruiting | USA | 0 |